Candida pneumonia: What we know and what we don't

Current Fungal Infection Reports

Volumn 3, Issue 1, 2009, Pages 21-31

  Barkauskas, Christina E ^a   Perfect, John R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; MICAFUNGIN; NUCLEOSIDE ANALOG; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VORICONAZOLE;

BRONCHUS SECRETION; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA HUMICOLA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL FEATURE; DIAGNOSTIC ERROR; DISEASE SEVERITY; FUNGUS ISOLATION; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; MICROBIAL COLONIZATION; NONHUMAN; PICHIA GUILLIERMONDII; PLEURA EMPYEMA; PULMONARY CANDIDIASIS; REVIEW; TREATMENT RESPONSE;

EID: 77949803821     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-009-0004-z     Document Type: Review

References (31)

1. Masur H, Rosen PP, Armstrong D: Pulmonary disease caused by Candida species. Am J Med 1977, 63:914-925.
2. Mohsenifar Z, Chopra SK, Johnson BL, Simmons DH: Candida pneumonia: experience with 20 patients. West J Med 1979, 131:196-200.
3. Haron E, Vartivarian S, Anaissie E, et al.Primary Candida pneumonia: experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993, 72:137-142.
4. Ko SC, Chen KY, Hsueh PR, et al.Fungal empyema thoracis: an emerging clinical entity. Chest 2000, 117:1672-1678.
5. Kanj SS, Welty-Wolf K, Madden J, et al.Fungal infection in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996, 75:142-156.
6. Chen KY, Ko SC, Hsueh PR, et al.Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001, 120:177-184.
7. Schwesinger G, Junghans D, Schroder G, et al.Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 2005, 48:176-180.
8. Roosen J, Frans E, Wilmer A, et al.Comparison of premortem clinical diagnoses in critically ill patients and subsequent autopsy findings. Mayo Clin Proc 2000, 75:562-567.
9. Meduri GU: Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med 1995, 16:61-93.
10. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
11. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society. Am J Respir Crit Care Med 2005, 171:388-416.
12. Wood GC, Mueller EW, Croce MA, et al.Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006, 32:599-603.
13. el-Ebiary M, Torres A, Fabregas N, et al.Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997, 156(2 Pt 1):583-590. (Pubitemid 27351999)
14. Murray PR, Van Scoy RE, Roberts GD: Should yeasts in respiratory secretions be identified? Mayo Clin Proc 1977, 52:42-45.
15. Eggimann P, Calandra T, Fluckiger U, et al.Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 2005, 31:1514-1521.
16. Barenfanger J, Arakere P, Cruz RD, et al.Improved outcomes associated with limiting identification of Candida spp. in respiratory secretions. J Clin Microbiol 2003, 41:5645-5649.
17. Pittet D, Monod M, Suter PM, et al.Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758.
18. Leon C, Ruiz-Santana S, Saavedra P, et al.A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
19. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
20. De Pauw B, Walsh TJ, Donnelly JP, et al.Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
21. Molnar TF: Current surgical treatment of thoracic empyema in adults. Eur J Cardiothorac Surg 2007, 32:422-430.
22. Colice GL, Curtis A, Deslauriers J, et al.Medical and surgical treatment of parapneumonia effusions: an evidence-based guideline. Chest 2000, 18:1158-1171. [Published erratum appears in Chest 2001, 19:319.]
23. Coote N, Kay ES: Surgical versus non-surgical management of pleural empyema. Cochrane Database Syst Rev 2008, 4:CD001956.
24. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al.Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004, 77:232-237.
25. Rijnders BJ, Cornelissen JJ, Slobbe L, et al.Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46:1401-1408.
26. Olson JA, Adler-Moore JP, Schwartz J, et al.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006, 50:2122-2131.
27. Fischman AJ, Alpert NM, Livni E, et al.Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 1993, 37:1270-1277. (Pubitemid 23166726)
28. Petraintiene R, Petraitis V, Groll AH, et al.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002, 46:12-23.
29. Garey KW, Rege M, Pai MP, et al.Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
30. Azoulay E, Timsit JF, Tafflet M, et al.Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117.
31. Delisle MS, Williamson DR, Perreault MM, et al.The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 2008, 23:11-17.